Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis - PubMed (original) (raw)
Observational Study
doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3.
Marit E Jørgensen 2, Bendix Carstensen 3, Frederik Persson 3, Hanne L Gulseth 4, Marcus Thuresson 5, Peter Fenici 6, David Nathanson 7, Thomas Nyström 7, Jan W Eriksson 8, Johan Bodegård 9, Anna Norhammar 10
Affiliations
- PMID: 28781064
- DOI: 10.1016/S2213-8587(17)30258-9
Observational Study
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Kåre I Birkeland et al. Lancet Diabetes Endocrinol. 2017 Sep.
Abstract
Background: In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovascular mortality and morbidity in new users of SGLT2 inhibitors versus new users of other glucose-lowering drugs, in a population with a broad cardiovascular risk profile.
Methods: CVD-REAL Nordic was an observational analysis of individual patient-level data from the Prescribed Drug Registers, Cause of Death Registers, and National Patient Registers in Denmark, Norway, and Sweden. All patients who filled a prescription for glucose-lowering drugs between 2012 and 2015 were included and followed up until Dec 31, 2015. Patients were divided into new users of SGLT2 inhibitors and new users of other glucose-lowering drugs. Each SGLT2 inhibitor user was matched with three users of other glucose-lowering drugs by use of propensity scores. Hazard ratios (HRs) were estimated by country (Cox survival model) and weighted averages were calculated. Cardiovascular outcomes investigated were cardiovascular mortality, major adverse cardiovascular events (cardiovascular mortality, myocardial infarction, and ischaemic or haemorrhagic stroke), hospital events for heart failure (inpatient or outpatient visit with a primary diagnosis of heart failure), non-fatal myocardial infarction, non-fatal stroke, and atrial fibrillation. We also assessed incidence of severe hypoglycaemia.
Findings: Matched SGLT2 inhibitor (n=22 830) and other glucose-lowering drug (n=68 490) groups were well balanced at baseline, with a mean follow-up of 0·9 (SD 4·1) years (80 669 patient-years) and mean age of 61 (12·0) years; 40% (36 362 of 91 320) were women and prevalence of cardiovascular disease was 25% (22 686 of 91 320). 94% of the total SGLT2 inhibitor exposure time was for use of dapagliflozin, with 5% for empagliflozin, and 1% for canagliflozin. Compared with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with decreased risk of cardiovascular mortality (HR 0·53 [95% CI 0·40-0·71]), major adverse cardiovascular events (0·78 [0·69-0·87]), and hospital events for heart failure (0·70 [0·61-0·81]; p<0·0001 for all). We did not identify significant differences between use of SGLT2 inhibitors and use of other glucose-lowering drugs for non-fatal myocardial infarction, non-fatal stroke, or atrial fibrillation. Compared with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with a decreased risk of severe hypoglycaemia (HR 0·76 [0·65-0·90]; p=0·001). For cardiovascular mortality, the differences were similar for the 25% of individuals with cardiovascular disease at baseline and those without (HR 0·60 [0·42-0·85] vs 0·55 [0·34-0·90]), while for major adverse cardiovascular events the HR in the group with cardiovascular disease at baseline was 0·70 (0·59-0·83) versus 0·90 (0·76-1·07) in the group without.
Interpretation: In a population of patients with type 2 diabetes and a broad cardiovascular risk profile, SGLT2 inhibitor use was associated with reduced cardiovascular disease and cardiovascular mortality compared with use of other glucose-lowering drugs-a finding consistent with the results of clinical trials in patients at high cardiovascular risk.
Funding: AstraZeneca.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
- SGLT2 inhibitors in the real world: too good to be true?
Fitchett D. Fitchett D. Lancet Diabetes Endocrinol. 2017 Sep;5(9):673-675. doi: 10.1016/S2213-8587(17)30259-0. Epub 2017 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 28781063 No abstract available.
Similar articles
- Can we go beyond surrogates?
Drexler A. Drexler A. J Diabetes. 2017 Nov;9(11):976-977. doi: 10.1111/1753-0407.12583. J Diabetes. 2017. PMID: 28692750 - Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Persson F, et al. Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8. Diabetes Obes Metab. 2018. PMID: 28771923 Free PMC article. - Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial. - Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B. Wu JH, et al. Lancet Diabetes Endocrinol. 2016 May;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8. Epub 2016 Mar 18. Lancet Diabetes Endocrinol. 2016. PMID: 27009625 Review.
Cited by
- New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.
El Khayari A, Hakam SM, Malka G, Rochette L, El Fatimy R. El Khayari A, et al. Genes Dis. 2023 Nov 23;11(6):101174. doi: 10.1016/j.gendis.2023.101174. eCollection 2024 Nov. Genes Dis. 2023. PMID: 39224109 Free PMC article. Review. - Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives.
Mondal S, Pramanik S, Khare VR, Fernandez CJ, Pappachan JM. Mondal S, et al. World J Cardiol. 2024 May 26;16(5):240-259. doi: 10.4330/wjc.v16.i5.240. World J Cardiol. 2024. PMID: 38817648 Free PMC article. Review. - Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study.
Kim M, Ha KH, Lee J, Park S, Oh KS, Bae DH, Lee JH, Kim SM, Choi WG, Hwang KK, Kim DW, Cho MC, Kim DJ, Bae JW. Kim M, et al. Korean Circ J. 2024 May;54(5):256-267. doi: 10.4070/kcj.2023.0234. Epub 2024 Mar 13. Korean Circ J. 2024. PMID: 38654455 Free PMC article. - Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis.
Cortesi PA, Antonazzo IC, Palladino P, Gnesi M, Mele S, D'Amelio M, Zanzottera Ferrari E, Mazzaglia G, Mantovani LG. Cortesi PA, et al. Acta Diabetol. 2024 Aug;61(8):1017-1028. doi: 10.1007/s00592-024-02276-3. Epub 2024 Apr 18. Acta Diabetol. 2024. PMID: 38634912 Free PMC article. - Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study.
Chang HC, Chen YY, Kuo TT, Lin YJ, Chien KL, Chang HY, Hung CL, Chung FP. Chang HC, et al. J Am Heart Assoc. 2024 Apr 16;13(8):e032397. doi: 10.1161/JAHA.123.032397. Epub 2024 Apr 9. J Am Heart Assoc. 2024. PMID: 38591334 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials